An exclusive central site of action for the proerectile effect of apomorphine, including not only the brain but also the spinal cord, is supported by extensive experimental data. Assuming that the mechanisms of action of apomorphine are similar in humans and animal models, its use for the treatment of erectile dysfunction (ED) validates the emerging idea that erectile response could be enhanced by acting directly within the central nervous system (CNS). It also emphasized the key role of the dopaminergic system in the control of erection. As exemplified with the clinical development of apomorphine, targeting the CNS does not rule out the occurrence of undesirable side effects. Because the rare event of syncope induced by apomorphine is not well understood, further research should be conducted to explore its possible mechanisms. In clinical practice, however, approved doses of apomorphine SL are well tolerated. It is noteworthy that no modification of sexual desire was observed with apomorphine. Indeed, drugs acting within the CNS may more likely interact with sexual desire than peripherally acting drugs, and care should be taken to assess this point in the future. Although our knowledge of the control of penile erection by the CNS is restricted, there are many potential sites for CNS-acting ED drugs. New centrally acting therapy for ED should concentrate on receptor targets more specific to erectile command. Clinical efficacy of new centrally-acting compounds will assess the well-founded purpose of this rationalization.
Introduction
The semisynthetic catecholic alkaloid apomorphine, a D1=D2 dopaminergic (DA) receptor agonist displays proerectile activity in various animal models (for extensive reviews see refs 1 and 2). Moreover, subcutaneous injections of low doses of apomorphine (0.25 -0.75 mg) induced penile erections in healthy adult males and in patients with erectile dysfunction (ED). 3, 4 Recent double-blind placebo controlled studies demonstrated that higher doses of apomorphine (2 -4 mg) delivered sublingually could increase the likelihood of penile erections in men with erectile dysfunction, leading to registration of apomorphine SL 2 and 3 mg in Europe in May 2001. 5, 6 A shift of predominantly antierectile sympathetic tone in favor of proerectile parasympathetic tone is likely at the origin of penile erection. 7 The sympathetic nuclei are located in the intermediolateral cell column and the dorsal grey commissure at the thoracolumbar level of the spinal cord, and the parasympathetic nuclei at the sacral level in the intermediolateral cell column. The spinal nuclei controlling penile erection are mastered by sensitive afferences from the genitalia and descending projections from the brain. Apomorphine facilitates penile erection by enhancing the release of proerectile neurotransmitter(s) at the peripheral level and=or by decreasing the permanent antierectile tone. It can do so by acting potentially at any site along the neural axis. In this brief overview are discussed outcomes from the first CNS-acting ED drug.
Central target of apomorphine in rats
A complete set of experimental data support an exclusively central target for the proerectile effect of peripherally delivered apomorphine in rats. First, apomorphine-induced erections are abolished by transection of the cavernous nerves 8 or pelvic nerves. 9 Apomorphine-induced erections are also inhibited by the central DA antagonist haloperidol, whereas they are unaffected by the peripheral DA antagonist domperidone. 10 In addition, intracavernous injection of apomorphine failed to elicit penile erection. 11 It has long been accepted that the target for the proerectile effect of apomorphine within the CNS is the paraventricular nucleus of the hypothalamus (PVN), as (i) injection of doses of apomorphine as low as 5 ng in the PVN induces penile erections; 12 and (ii) penile erections induced by peripheral delivery of apomorphine are antagonized by a preceding injection of SCH23390 (D1 antagonist) or sulpiride (D2 antagonist) in the PVN. 11 However, recent data suggest that the spinal cord might also be a target for the proerectile effect of apomorphine. We have shown that apomorphine delivered at the lumbosacral level with an intrathecal catheter elicited erectile activity in anesthetized rats. 13 Moreover, the ability of apomorphine to induce penile erection in spinalized rats has been demonstrated in both anesthetized and conscious rats. 9 In this era of growing interest for the neuropharmacology of erection, it is worth mentioning that apomorphine is the only proerectile drug for which an exclusive central effect has been undoubtedly demonstrated. Potential CNS-acting ED drug, such as the alpha-MSH agonists melanotan II and PT-141 should undergo a comprehensive experimental approach similar to the one achieved with apomorphine before claiming for a central mechanism of action. 14, 15 Induction of penile erections by central injection of alpha-MSH in rodents does not establish that alpha-MSH analogs such as PT-141 or melanotan II act through the same mechanism when given peripherally. Experimentally, it is a key point to demonstrate that the proerectile activity observed upon peripheral delivery of these drugs can be abolished by the injection of a suitable antagonist in the central nervous system. In this line, the ability of these compounds to cross the blood brain barrier and the dosings required for inducing erectile activity after peripheral and central injection are essential outcomes in assessing their site of action. Some hexarelin analogue peptides were also shown to display proerectile activity when injected in the PVN of conscious rats, likely by recruiting a new class of receptors. 16 More recently, their proerectile activity have been assessed when delivered peripherally, but it remains to be determined whether this proerectile activity was mediated by the central nervous system. 17 Efficacy in clinical trials: are animal models predictive for a CNS acting drug?
Phase III clinical trials with apomorphine SL (Uprima 1 ) included more than 5000 patients and over 120 000 doses. The primary efficacy endpoint in most studies was the presence or absence 'of an erection firm enough for intercourse' in the view of the patient and their partner. All data have been compiled from diary records and records were made at each attempt. A cross study analysis of the results of apomorphine SL trials shows that 54% of the attempts resulted in an erection firm enough for intercourse at the dosing of 4 mg versus 33% with placebo. 18 In a more recent study, the dosing of 3 mg was compared with placebo. The number of attempts resulting in an erection firm enough for intercourse was 47% on 3 mg apomorphine and 32% on placebo. 6 In all cases, successful attempts were significantly greater upon apomorphine SL (Uprima 1 ) than placebo. It is noteworthy that these studies are consistent in their methodology and primary end points, and distinct from other series of studies on PDEV inhibitors. 5, 19 Assuming that apomorphine acts centrally in humans as it does in the rat, the fundamental outcome of these clinical trials is that a drug targeting the central nervous system has proved efficacy for the on demand treatment of erectile dysfunction. The proerectile mechanisms of apomorphine differs in rats (s.c. or i.v.) and humans (s.l.) at the same dosing, although it is evident that such comparison may be biased by an array of interspecies differences not specifically related to the neurophysiology of the sexual response. Whereas apomorphine increases the likelihood of a patient to get an erection in a relevant sexual context, it clearly induces erection at the same dosing in rats out of any sexual context (on a body weight basis, the dosings currently used experimentally in rats are similar to the ones used clinically in humans, i.e. 50 -70 mg=kg). Interestingly, close relatives to humans such as Rhesus monkeys are also insensitive to the prosexual activity of apomorphine out of sexual context. 20 Those interspecies differences are likely caused by differences in apomorphine sensitivity of the proerectile response. In support of this assertion, induction of penile erections have been reported in several cases of patients with Parkinson's disease when self-injecting 3 mg bolus apomorphine s.c. at least more than four times a day. 21 The weaker sensitivity of the erectile response to apomorphine in humans points to the differences in the neurophysiology and neuropharmacology of the rat, monkey and human central nervous system. The comparison of the experimental and clinical results obtained with apomorphine underlines the cautiousness that should be exerted when extrapolating results obtained in animal models, and particularly in rodents, to humans. This difficulty has been exemplified by yohimbine, which displays a significant proerectile efficacy in rats whereas its proerectile effect in humans is still a matter of debate. 22 Nevertheless, apomorphine does display a significant proerectile activity in human and rats, and hence validate the use of rats as an animal Apomorphine SL: the first CNS-acting ED drug F Giuliano and J Allard model in the development of CNS-drugs aiming at treating erectile dysfunctions.
Side effects of apomorphine in humans
Targeting the central nervous system obviously does not rule out the occurrence of side effects, and the clinical use of apomorphine SL is hindered by the occurrence of nausea and, rarely, syncope. 23 At the 6 mg dosing, mild to moderate nausea was reported in 34% (severe nausea, < 3%) of patients versus less than 5% with placebo. At the approved doses of 2 and 3 mg, the incidence of nausea, which is predominantly mild in nature, is approximately 7%. There is evidence from clinical trials of a tolerance to first dose nausea, where nausea occurs. At approved doses, syncope, the most adverse side effect, occurs in less than 0.2% of patients. On a per attempt basis, this figure is very much lower. At higher than approved doses, the incidence of all adverse events and in particular syncope is greater, while doses higher than 3 mg do not offer any significant incremental efficacy. For this reason, the highest approved dose of apomorphine SL is 3 mg. Apomorphine-induced syncope is commonly accepted to be a vasovagal fainting induced by hypotension and might be of peripheral and=or central origin. 24 Whether the concomitant delivery of a peripheral D2 antagonist, such as domperidone, could alleviate syncope and=or nausea induced by apomorphine is an open question. 25 The tolerability and safety profile of apomorphine SL led to a narrow therapeutical window for the treatment of erectile dysfunction. Future CNS acting ED drugs should be developed from compounds displaying first and foremost proerectile activity, based on current basic knowledge on the central pharmacology of sexual functions. This requires the recognition of proerectile targets within the CNS, which will not be possible before an improvement of our knowledge of the control of penile erection by the CNS.
Apomorphine and libido
Heightened libido has been noticed in patients with Parkinson's disease after increased self-administered apomorphine (4 -10 times 3 mg s.c. injections a day). 21 Such an impact of apomorphine on libido is in agreement with experimental data obtained on rat sexual behavior, clearly showing a positive effect of dopaminergic agonist on sexual motivation in the limbic areas. Nevertheless, in clinical trials with sublingual apomorphine up to 6 mg, there was no effect on sexual desire according to the IIEF questionnaire, likely because of the low dosings used in these trials. 18 Nevertheless, targeting the central nervous system raises the possibility to modify sexual desire, which can be considered as positive or negative depending on individual cases. Accordingly, a recent study established that melanotan II, a potentially centrally acting proerectile drug, increased sexual desire upon acute dosing. 26 
Conclusion
The potential proerectile effect of apomorphine was experimentally evidenced more than 20 y ago. 10 Apomorphine was approved for the treatment of erectile dysfunction in Europe only this year. Theoretically, a CNS acting ED drug may more likely overcome the cardio-vascular effects inherent to drugs targeting directly the erectile tissue, because of the similarities existing between the molecular processes involved in the regulation of the vascular tone and local mechanisms of penile erection. Ideally, CNS acting ED drugs should target neuronal pathway specifically involved in the control of penile erection. Among the known candidates are oxytocinergic and a-MSH agonists and hexarelin analog peptides.
